Nanoparticles for combination drug therapy.

Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted tissues and cells. This vast level of pharmacological control is intriguing, especially from the perspective of tailoring personalized treatments with maximized therapeutic synergy for individual patients. Here, we discuss promising formulations and opportunities to employ advanced screening tools and new animal models of disease that can improve chances for successful clinical translation.

[1]  Eduardo D Sontag,et al.  Mechanism-independent method for predicting response to multidrug combinations in bacteria , 2012, Proceedings of the National Academy of Sciences.

[2]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[3]  Zongxi Li,et al.  Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.

[4]  Robert Langer,et al.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.

[5]  J. Mesirov,et al.  MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma , 2012, Science Signaling.

[6]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[7]  Jan E Schnitzer,et al.  Overcoming in vivo barriers to targeted nanodelivery. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[8]  Michael Costanzo,et al.  Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.

[9]  Mark B. Carter,et al.  Erratum: The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers (Nature Materials (2011) 10 (389-397)) , 2011 .

[10]  K. Gelmon,et al.  Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[11]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[12]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[13]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[14]  R. Kamm,et al.  Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function , 2012, Proceedings of the National Academy of Sciences.

[15]  Li Tang,et al.  Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. , 2012, ACS nano.

[16]  Lawrence Mayer,et al.  In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.

[17]  M. Bawendi,et al.  Design Considerations for Tumor-Targeted Nanoparticles , 2009 .

[18]  Jan E. Schnitzer,et al.  Caveolae: mining little caves for new cancer targets , 2003, Nature Reviews Cancer.

[19]  S. Kopetz,et al.  The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men , 2012, Clinical Cancer Research.

[20]  S. Mitragotri,et al.  Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. , 2013, ACS nano.

[21]  Richard A Flavell,et al.  Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. , 2012, Nature materials.

[22]  S. Nie,et al.  A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. , 2010, ACS nano.

[23]  S. Gambhir,et al.  Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. , 2005, Cancer research.

[24]  Hak Soo Choi,et al.  Design considerations for tumour-targeted nanoparticles. , 2010, Nature nanotechnology.

[25]  J. Woodcock,et al.  Development of novel combination therapies. , 2011, The New England journal of medicine.

[26]  John S. Condeelis,et al.  Chemotaxis in cancer , 2011, Nature Reviews Cancer.

[27]  Roy Kishony,et al.  Drug interactions and the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.

[28]  Q. Teng,et al.  Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis , 2013, PloS one.

[29]  Francoise Remacle,et al.  Hypoxia induces a phase transition within a kinase signaling network in cancer cells , 2013, Proceedings of the National Academy of Sciences.

[30]  H. Woo,et al.  Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. , 2013, Cell reports.

[31]  Omid C Farokhzad,et al.  Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. , 2011, Accounts of chemical research.

[32]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[33]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[34]  Rong Fan,et al.  Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells , 2011, Proceedings of the National Academy of Sciences.

[35]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[36]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[37]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.